To fate of exogenous glucagon-like peptide I (GLP-I)(7–36) amide was studied in
nondiabetic and type II diabetic subjects using a combination of high-pressure liquid …

Using specific radioimmunoassays, we studied the occurrence of amidated and glycine-
extended glucagon-like peptide I (GLP-I) molecules in the human small intestine and …

Effects of human glucagon-like peptide I (GLP-I)(7–36) amide were examined in volunteers
having insulin-dependent diabetes mellitus (IDDM) with residual C-peptide (CP) secretion …

Glucagonlike peptide I (7–37)[GLP-I-(7–37)], encoded with glucagon and glucagonlike
peptide II and intervening peptide II in the rat and human glucagon gene, is processed from …

Glucagon-like peptide I (GLP-I) decreases plasma glucose in type II diabetic patients and in
healthy subjects indirectly by stimulation of insulin and inhibition of glucagon secretion …

The biological effects and the metabolism of the intestinal hormone glucagonlike peptide-1 7–
36 amide and glucagonlike peptide-1 7–37 were studied in normal healthy subjects. GLP-1 …

Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important
factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential …

The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is
known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the …

Summary Glucagon-like peptide 1 (GLP-1)(7-36 amide) is a physiological incretin hormone
that is released after nutrient intake from the lower gut and stimulates insulin secretion at …

We have previously shown that type 2 diabetic patients have decreased plasma
concentrations of glucagon-like peptide 1 (GLP-1) compared with healthy subjects after …